4334
-
-
Our expertsJulien joined SCOR Alternative Solutions in 2022, as an underwriter, working for corporates clients in the EMEA region, and also contributing to the advisory, analytics within the team.
-
Our expertsRoshan is a longevity specialist with more than 10 years of experience in the field.
-
- Review of neurological, developmental, and mental health conditions
-
Drugs developed for the treatment of diabetes such as semaglutide (marketed as Ozempic or Wegovy), liraglutide (Saxenda), and tirzepatide (Mounjaro or Zepbound) are being used to decrease the weight of obesity risks:
-
-
-
-
Our expertsHelen joined SCOR as Head of Underwriting for Life and Health in the UK & Ireland in July 2024.
-
Press ReleasesFollowing the acquisition, SCOR intends to file a simplified public tender offer
-
Our expertsAs a former Senior Vice President and now Head of US Financial Solutions, Brian leads the Financial Solutions team which uses reinsurance applicati
-
